IRIS
MARTINELLI, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.623
NA - Nord America 3.222
AS - Asia 759
OC - Oceania 13
SA - Sud America 7
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.629
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.183
IE - Irlanda 1.254
IT - Italia 651
GB - Regno Unito 374
UA - Ucraina 353
DE - Germania 347
SG - Singapore 289
FR - Francia 249
CN - Cina 242
SE - Svezia 107
FI - Finlandia 105
GR - Grecia 105
TR - Turchia 88
KR - Corea 58
CA - Canada 35
BE - Belgio 21
VN - Vietnam 21
PK - Pakistan 20
CZ - Repubblica Ceca 17
IN - India 17
NL - Olanda 12
HK - Hong Kong 8
AU - Australia 7
AT - Austria 6
IR - Iran 6
NZ - Nuova Zelanda 6
BR - Brasile 4
CH - Svizzera 4
ES - Italia 4
MX - Messico 4
RU - Federazione Russa 4
MK - Macedonia 3
BD - Bangladesh 2
EU - Europa 2
GI - Gibilterra 2
PE - Perù 2
PL - Polonia 2
TW - Taiwan 2
AR - Argentina 1
EG - Egitto 1
HU - Ungheria 1
JP - Giappone 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
MA - Marocco 1
MY - Malesia 1
RO - Romania 1
RS - Serbia 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 7.629
Salva come PNG Salva come JPEG
Città #
Dublin 1.240
Chandler 613
Jacksonville 580
Santa Clara 189
Singapore 181
Princeton 171
Bremen 146
Roxbury 143
Medford 131
New York 128
Ann Arbor 106
Naples 102
Wilmington 78
Caserta 75
Beijing 74
Munich 64
Boardman 54
Cambridge 46
Des Moines 43
San Mateo 41
Nanjing 37
Woodbridge 36
Seoul 35
Napoli 32
Los Angeles 30
Ashburn 26
Elora 22
Brussels 21
Dong Ket 20
Norwalk 20
Houston 18
Mountain View 17
Milan 15
Brno 14
Helsinki 14
Nanchang 13
Rome 12
Düsseldorf 10
Lappeenranta 10
Redwood City 10
Auburn Hills 9
Jinan 9
Shanghai 9
Tianjin 9
Bahawalpur 8
Istanbul 8
Amsterdam 7
Cava Dei Tirreni 7
Pozzuoli 7
Venice 7
Guangzhou 6
Taiyuan 6
Vienna 6
Florence 5
Hong Kong 5
Ottawa 5
Shenyang 5
Taizhou 5
Anantapur 4
Battipaglia 4
Castellammare Di Stabia 4
Fairfield 4
Hangzhou 4
Hebei 4
Lanzhou 4
Monte Di Procida 4
Ningbo 4
Redmond 4
Sennori 4
Toronto 4
Zhengzhou 4
Zurich 4
Athens 3
Changchun 3
Chengdu 3
Colle di Val d'Elsa 3
Ercolano 3
Giugliano in Campania 3
Groningen 3
Hanover 3
Hyderabad 3
Kunming 3
Lodi 3
London 3
Madrid 3
Montecorvino Rovella 3
Mugnano Di Napoli 3
Mugnano di Napoli 3
Nola 3
Seregno 3
Viareggio 3
Andover 2
Avellino 2
Benevento 2
Brdo 2
Caivano 2
Casoria 2
Central 2
Chicago 2
Cinquevie 2
Totale 4.871
Salva come PNG Salva come JPEG
Nome #
ONCOLOGIA MEDICA 148
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 103
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 95
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 87
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 87
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 83
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 81
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 80
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 77
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 77
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 77
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 72
TRASTUZUMAB RESISTANCE IN BREAST CANCER 72
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 70
Farmacogenomica e cancro colorettale 69
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 68
AXL is an oncotarget in human colorectal cancer 67
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 67
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 66
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 64
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 64
Chemoradiotherapy as adjuvant treatment of gastric cancer 63
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 62
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 61
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 61
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 60
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 60
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 60
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 59
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 59
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 59
Combination of anti-EGFR drugs and other molecular targeted agents as anti-cancer strategy 59
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 59
Beyond N staging in colorectal cancer: Current approaches and future perspectives 58
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 58
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 58
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 56
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 56
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 56
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 56
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 55
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? 55
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 55
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: A phase II study 54
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 54
Targeting EGFR in Pancreatic Cancer Treatment. 54
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 54
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 52
Tumori neuroendocrini (NETs) 52
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 52
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 52
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 52
Preoperative chemo-radiotherapy for carcinoma of the esophagus 51
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. 51
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 51
The new European gold standard treatment for rectum cancer 50
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 50
Erlotinib in cancer treatment 50
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy 49
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 49
It is finally time for adjuvant therapy in melanoma 49
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 49
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 49
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 49
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study 48
MEK inhibitor as a single agent and in combination with everolimus or sorafenib in a panel of colorectal cancer cell lines: implication for multitargeted approach 47
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. 47
PHASE I/II STUDY OF FOLFIRI PLUS THE MEK1/2 INHIBITOR PIMASERTIB (MSC1936369B) AS SECOND-LINE TREATMENT FOR KRAS MUTATED METASTATIC COLORECTAL CANCER 47
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. 47
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis 47
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 47
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer 46
Metformin in lung cancer: rationale for a combination therapy 46
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 46
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 46
OPTIMIZING THERAPEUTIC COMBINATIONS OF A SELECTIVE MEK 1/2 INHIBITOR (PIMASERTIB) WITH PI3K/ MTOR INHIBITORS OR WITH MULTI-TARGETED KINASE INHIBITORS IN PIMASERTIB-RESISTANT HUMAN LUNG AND COLORECTAL CANCER CELLS 46
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. 46
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 46
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 46
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 46
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 45
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 45
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 45
Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy 45
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study 44
Resistance mechanisms of tumour cells to EGFR inhibitors 44
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 44
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells 42
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 42
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 42
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 41
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer 41
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 41
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 40
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 40
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 40
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 40
The use of xenograft models for the selection of cancer treatments with the EGFR as an example 39
Combination therapy with anti-EGFR monoclonal antibodies in the treatment of NSCLC. 39
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. 39
Totale 5.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.592
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.592
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020552 0 0 0 0 102 22 145 73 86 69 42 13
2020/2021955 89 15 103 53 138 12 129 95 34 116 120 51
2021/20221.159 54 17 23 23 340 24 42 35 54 100 107 340
2022/20232.491 253 50 35 213 295 209 7 152 1.155 17 57 48
2023/20241.000 94 37 38 51 337 143 19 24 11 14 74 158
2024/2025631 57 105 54 109 306 0 0 0 0 0 0 0
Totale 8.071